HCV elimination:is the bulk of the iceberg being missed?
Eric Kalo1
Asma Baig2
Alison Derrett3
Scott Read4
Golo Ahlenstiel5
1.Blacktown Clinical School,School of Medicine,Western Sydney University,Blacktown,NSW,Australia;Blacktown Mount Druitt Hospital,Western Sydney Local Health District,Blacktown,NSW,Australia2.Blacktown Mount Druitt Hospital,Western Sydney Local Health District,Blacktown,NSW,Australia3.Western Sydney Local Health District,Westmead,NSW,Australia4.Blacktown Clinical School,School of Medicine,Western Sydney University,Blacktown,NSW,Australia;Blacktown Mount Druitt Hospital,Western Sydney Local Health District,Blacktown,NSW,Australia;Storr Liver Centre,The Westmead Institute for Medical Research,University of Sydney,Westmead,NSW,Australia5.Blacktown Clinical School,School of Medicine,Western Sydney University,Blacktown,NSW,Australia;Blacktown Mount Druitt Hospital,Western Sydney Local Health District,Blacktown,NSW,Australia;Western Sydney Local Health District,Westmead,NSW,Australia;Storr Liver Centre,The Westmead Institute for Medical Research,University of Sydney,Westmead,NSW,Australia
摘要：Introduction
In 2016,the Australian government spent more than 1 billion dol-lars to make hepatitis C virus(HCV)direct-acting antivirals(DAAs)available to all as part of a promising plan to eradicate HCV within a generation[1].
机标关键词：beingbulkeliminationicebergmissed
论文发表日期：2024-12-30
在线出版日期：2026-07-17（本平台首次上网日期，不代表文献的发表时间）
页数：2( 623-624 )